gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant]
gabapentin enacarbil
RxCUI: 1101339
What the CMS Formulary Data Shows for gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant]
Per the CMS 2026 Part D formulary file, gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] (RxNorm concept RXCUI 1101339, generic name gabapentin enacarbil) appears on 4 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.
Real-world access to gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 6,276 Part D beneficiaries filled gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] in 2023, with total plan-and-beneficiary spending of $32,997,342 and an average per-beneficiary annual cost of $5,257.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 6,276
- Total spending
- $32,997,342
- Avg per beneficiary
- $5,257.70
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $0 | MA |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T4 | No | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T4 | No | $147.20 | MA |
Frequently Asked Questions
Is gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] covered by Medicare Part D?
Yes, gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] on Medicare Part D plans?
gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.
Does gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] require prior authorization?
0% of Part D formularies require prior authorization for gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant]?
In 2023, total Medicare Part D spending on gabapentin enacarbil 600 MG Extended Release Oral Tablet [Horizant] was $32,997,342, covering 6,276 beneficiaries. The average spend per beneficiary was $5,257.70.
Read our methodology - how this data is sourced, computed, and verified.